Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands.
Infectious Diseases Biomarkers, Janssen Research and Development, Beerse, Belgium.
J Infect Dis. 2022 Apr 19;225(8):1471-1476. doi: 10.1093/infdis/jiaa614.
Long-term viremia control in chronic HBV patients occurs either spontaneously in inactive carrier (IC) patients or therapy-induced by nucleos(t)ide analogues (NUC). To better understand the characteristics of viremia control, we evaluated gene expression in purified leukocyte subsets from IC versus NUC-treated patients, and evaluated the putative modulatory effects of hepatitis B surface antigen (HBsAg). We observed that gene expression in NUC-treated patients differed markedly from IC patients, especially in dendritic cells, monocytes, and CD8+ T cells, while serum HBsAg levels had little effect. Nevertheless, based on our findings it cannot be excluded that HBsAg may act locally in the infected liver or preferentially affects HBV-specific cells.
慢性乙型肝炎患者的长期病毒血症控制要么自发地发生在非活动型携带者（IC）患者中，要么通过核苷（酸）类似物（NUC）治疗诱导。为了更好地了解病毒血症控制的特征，我们评估了来自 IC 患者与 NUC 治疗患者的纯化白细胞亚群中的基因表达，并评估了乙型肝炎表面抗原（HBsAg）的潜在调节作用。我们观察到，NUC 治疗患者的基因表达与 IC 患者明显不同，尤其是树突状细胞、单核细胞和 CD8+T 细胞，而血清 HBsAg 水平几乎没有影响。然而，根据我们的发现，不能排除 HBsAg 可能在感染的肝脏中局部发挥作用，或者优先影响 HBV 特异性细胞。
